Use of sodium–glucose cotransporter‐2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020

Documenti analoghi

• Clinical characteristics and economic impact of acute hospitalisations due to bronchiectasis exacerbations among adult Indigenous Australians in the Top End Northern Territory
  di: Thomas Berhane, et al.
  Pubblicazione: (2025)
• Sodium‐glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real‐world case series
  di: Anthea Tsatsaronis, et al.
  Pubblicazione: (2024)
• Rapid chronic kidney disease progression in younger, First Nations patients in the Northern Territory
  di: Winnie Chen, et al.
  Pubblicazione: (2025)
• Opportunistic screening for diabetes among urban Aboriginal adults during emergency department attendance
  di: William Yu, et al.
  Pubblicazione: (2025)
• Is semaglutide cost‐effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
  di: Satyen Hargovan, et al.
  Pubblicazione: (2025)